On July 23, 2009, the Vaccines and Related Biological Products Advisory Committee of the FDA is slated to discuss clinical trials to support the use of vaccines against the 2009 H1N1 influenza virus, also known as swine flu.
The following are some of the little-known companies developing potential vaccines for swine flu, which are garnering attention.
...
Hemispherx Biopharma Inc. (HEB) is yet other stock, which continues to rally on swine flu concerns. The company will provide an update on its influenza research initiatives including the experimental programs planned or underway in Pacific Rim countries, Australia, South America and the United States today (July 22).
The company is awaiting FDA approval of its experimental drug Ampligen for chronic fatigue syndrome. Ampligen is also in preclinical testing for avian flu in the U.S., Japan and Canada.
Last month, Hemispherx's collaborative influenza vaccine development partner in Japan, Biken announced its plan to invest a total of 35 billion Yen (US $350 million) to expand its Flu production capacity in Kanonji City. The Japanese research teams believe that Ampligen is an essential co-ingredient to provide experimental efficacy with the Biken vaccine. HEB closed at $3.31, up nearly 33% on Tuesday.
Hier der Link:
http://www.learningmarkets.com/index.php/...-bcrx-heb-nvax-btahy.html |
